Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After Demonstrating Safety and Tolerability in Phase 1 Study
December 19, 2017, SOUTH SAN FRANCISCO, Calif., Dec 19, 2018
Second Genome Launches Study of the Relationship Between Microbiome and Central Nervous System in Autism Spectrum Disorders
October 3, 2017,Fast-Track SBIR grant applied towards the development of a commercial platform for discovery and validation of key microbial metabolites linked to CNS disorders
Second Genome Named Technology Pioneer by World Economic Forum
June 4, 2017,
Second Genome Announces Appointments in Human Resources, Finance to Support Corporate Growth
December 7, 2016, South San Francisco, CASecond Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Jim Sjoerdsma as executive vice president of human resources and Brian Dowd as senior vice president of finance.
Second Genome Partners with King’s College London to Evaluate the Influence of the Microbiome in Landmark EAT Study
October 11, 2016, South San Francisco, CA
Monsanto Collaborates with Second Genome to use Microbiome Technology Platform to Accelerate Protein Discovery
September 6, 2016, St. Louis, MO and South San Francisco, CAMicrobial genome analysis using big data science, bioinformatics and machine learning expected to drive discovery of microbiome-based solutions that can help farmers better manage on-farm challenges
Second Genome Appoints Glenn Nedwin, Ph.D., as Chief Executive Officer
July 13, 2016, South San Francisco, CASecond Genome, Inc., a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, today announced the appointment of Glenn Nedwin, Ph.D., as chief executive officer, president and member of the company’s board of directors. Dr. Nedwin joins Second Genome as the company accelerates the translation of its microbiome discoveries into a pipeline of clinical opportunities.
Second Genome Secures $42.6 Million in Series B Financing Led by Pfizer Venture Investments and Roche Venture Fund
April 20, 2016, South San Francisco, CASecond Genome, Inc., a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, today announced that it has closed an oversubscribed Series B investment round with $42.6 million in financing. The round was co-led by Pfizer Venture Investments and Roche Venture Fund, and brings the combined total investment in the company to $59 million.